FrancophonIA/ELRC3.0 huggingface dataset:
English: Levetiracetam Hospira contains sodium
Maltese: Levetiraceram Hospira fih sodium
English: Four embryo-foetal development studies were performed in rabbits covering doses of 200, 600, 800, 1,200 and 1,800 mg/kg/day.
Maltese: Erba' studji dwar l-iżvilupp tal-embriju u l-fetu saru fil-fniek li koprew dożi ta' 200, 600, 800, 1200 u 1800 mg/kg/ġurnata.
English: It was concluded that levetiracetam was not different (non-inferior) from placebo with regard to the change from baseline of the Leiter-R Attention and Memory, Memory Screen Composite score in the per-protocol population.
Maltese: Kien konkluż li levetiracetam ma kienx differenti (mhux inferjuri) mill-plaċebo fejn jidħol il-bidla mill-linja bażi tal-Leiter-R Attention and Memory, Memory Screen Composite score fil-popolazzjoni skont il-protokol.
English: One vial contains 500 mg/5 ml levetiracetam.
Maltese: Kunjett wieħed fih 500 mg/5 ml levetiracetam.
English: The apparent body clearance was 1.1 ml/min/kg.
Maltese: It-tneħħija fil-ġisem deher li kien 1.1 ml/min/kg.
English: Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX14.
Maltese: Kategorija farmakoterapewtika: mediċini għall-kontra l-epilessija, mediċini għall-kontra l-epilessija oħra, Kodiċi ATC:
English: From 50 kg
Maltese: Minn 50 kg
English: Levetiracetam efficacy was established in a 24-week double-blind, placebo-controlled study which included adults, adolescents and a limited number of children suffering from idiopathic generalized epilepsy with primary generalized tonic-clonic (PGTC) seizures in different syndromes (juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence epilepsy, or epilepsy with Grand Mal seizures on awakening).
Maltese: L-effikaċja ta' levetiracetam kienet stabbilita fi studju double-blind, ikkontrollata minn plaċebo ta' 24 ġimgħa, li inkludiet adulti, adolexxenti u numru limitat ta' tfal b'epilessija tat-tip ġeneralizzat idjopatiku b'aċċessjonijiet ġeneralizzati primarji tat-tip tonic-clonic (PGTC) f'sindromi (epilessija mijoklonika ġovanili, epilessija assenti ġovanili, epilessija assenti tat-tfal, jew epilessija b'aċċessjonijiet Grand Mal meta jqumu).
English: Dose in adults and adolescents (from 16 years of age):
Maltese: Doża fl-adulti u adolexxenti (minn 16-il sena):
English: A peri- and post-natal development study was performed in rats with levetiracetam doses of 70, 350 and 1,800 mg/kg/day.
Maltese: Studju fuq l-iżvilupp li sar waqt u wara t-tqala sar fil-firien b'dożi ta' levetiracetam ta' 70, 350 u 1800 mg/kg/ġurnata.
English: As in adults, there is no evidence of clinically significant medicinal product interactions in paediatric patients receiving up to 60 mg/kg/day levetiracetam.
Maltese: Bħal fl-adulti, m'hemm ebda evidenza klinikament sinifikanti ta' effetti ta' mediċini oħra f'pazjenti pedjatriċi li jieħdu sa 60 mg/kg/ġurnata ta' levetiracetam.
English: 250 to 750 mg twice daily
Maltese: 250 sa 750 mg darbtejn kuljum
English: 5 to 15 mg/kg (0.05 to 0.15 ml/kg) twice daily
Maltese: 5 sa 15 mg/kg (0.05 sa 0.15 ml/kg) darbtejn kuljum
English: • encephalopathy (see sub-section “Tell your doctor immediately” for a detailed description of symptoms);
Maltese: • enċefalopatija (ara sottosezzjoni “Għid lit-tabib tiegħek immedjatament”) għal deskrizzjoni dettaljata tas-sintomi
English: In paediatric patients (4 to 16 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 198 patients and had a treatment duration of 14 weeks.
Maltese: F'pazjenti pedjatriċi (4 sa 16-il sena), l-effiċjenza ta' levetiracetam kienet murija fi studju doubleblind ikkontrollat minn plaċebo li inkluda 198 pazjent b'trattament li dam 14-il ġimgħa.
English: The safety profile of levetiracetam is generally similar across age groups (adult and paediatric patients) and across the approved epilepsy indications.
Maltese: Il-profil ta' sigurtà ta' levetiracetam huwa ġeneralment simili fil-gruppi ta' età (pazjenti adulti u pedjatriċi) u flindikazzjonijiet ta' epilessija indikati.
English: One maximum single dose of Levetiracetam Hospira concentrate contains 2.5 mmol (or 57 mg) of sodium (0.8 mmol (or 19 mg) of sodium per vial).
Maltese: Doża waħda massima ta' konċentrat ta' Levetiracetam Hospira fiha 2.5 mmol (jew 57 mg) ta' sodium (0.8 mmol (jew 19 mg) ta' sodium f'kull kunjett).
English: • Dextrose 50 mg/ml (5%) solution for injection
Maltese: • Soluzzjoni għall-injezzjoni ta' dextrose 50 mg/ml (5%)
English: The CLcr in ml/min/1.73 m2 may be estimated from serum creatinine (mg/dl) determination, for young adolescents and children using the following formula (Schwartz formula):
Maltese: Il-CLcr f'ml/min/1.73 m2 tista' tigi kkalkulata mill-livell ta' kreatinina fis-serum (mg/dl), għal adolexxenti żgħar u tfal, billi tuża din il-formula (formula Schwartz):
English: Immune system disorders
Maltese: Mard tas-sistema immuni
English: With continued long-term treatment, 11.4% of the patients were seizure-free for at least 6 months and 7.2% were seizure-free for at least 1 year.
Maltese: Bi trattament li jikompla fit-tul, 11.4 % tal-pazjenti ma kellhomx aċċessjonijiet għal mill-inqas 6 xhur u 7.2 % ma kellhomx aċċessjonijiet għal mill-inqas sena.
English: Following single oral dose administration (20 mg/kg) to epileptic children (6 to 12 years), the half-life of levetiracetam was 6.0 hours.
Maltese: Wara li ngħatat doża orali waħda li tammonta għal 20 mg/kg lil tfal bl-epilessija (6 sa 12 il-sena), il-half life ta' levetiracetam kienet ta' 6.0 sigħat.
English: The fractional removal of levetiracetam was 51% during a typical 4-hour dialysis session.
Maltese: It-tneħħija parzjali ta' levetiracetam kienet ta'51 % waqt sezzjoni tad-dijaliżi tipika li damet 4 sigħat.
English: Results related to behavioural and emotional functioning indicated a worsening in levetiracetam treated patients on aggressive behaviour as measured in a standardised and systematic way using a validated instrument (CBCL - Achenbach Child Behaviour Checklist).
Maltese: Riżultati li għandhom x'jaqsmu malfunzjoni tal-imġiba u dik emozjonali juru aggravament fil-pazjenti trattati b'levetiracetam f'imġiba aggressiva kif imkejjel b'mod standardizzat u sistematiku bl-użu ta' strument validat (CBCLAchenbach Child Behaviour Checklist).
English: Add-on therapy for adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more The initial therapeutic dose is 500 mg twice daily.
Maltese: Terapija aġġuntiva għal adulti (≥18 sena ) u adolexxenti (12 sa 17-il sena) li jiżnu 50 kg jew iżjed.
English: In adults, levetiracetam efficacy has been demonstrated in 3 double-blind, placebo--controlled studies at 1,000 mg, 2,000 mg, or 3,000 mg/day, given in 2 divided doses, with a treatment duration of up to 18 weeks.
Maltese: F'adulti, l-effiċjenza ta' levetiracetam kien muri fi 3 studji double-blind ikkontrollati minn plaċebo f dożi ta' 1000 mg, 2000 mg, jew 3000 mg/ kuljum, mogħtija f'2 dożi separati, b'trattament li dam sa 18 il-ġimgħa.
English: A doctor or a nurse will administer you Levetiracetam Hospira as an intravenous infusion.
Maltese: Tabib jew infermier ser jamministralek Levetiracetam Hospira bħala infużjoni ġol-vina.
English: The dialyser extraction efficiency is 60% for levetiracetam and 74% for the primary metabolite.
Maltese: L-effiċjenza tal-estrazzjoni tad-dijaliżi hija ta' 60 % għal levetiracetam u ta' 74 % għall-prodott ewlieni tal-metaboliżmu.
English: Each ml contains 100 mg levetiracetam.
Maltese: Kull ml fiha 100 mg levetiracetam.
English: Adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
Maltese: Terapija aġġuntiva fit-trattament ta' aċċessjonijiet mijokloniċi f'adulti u adolexxenti min 12-il sena b'epilessija mijoklonika ġovanili.
English: 44.6% of the levetiracetam treated patients and 19.6% of the patients on placebo had a 50% or greater reduction from baseline in the partial onset seizure frequency per week.
Maltese: 44.6 % ta' pazjenti fuq levetiracetam u 19.6 % ta' pazjenti fuq il-plaċebo kellhom tnaqqis ta' 50 % jew iżjed mill-linja bażi fil-frekwenza fil-ġimgħa ta' aċċessjonijiet tat-tip parzjali.
English: 5 ml glass vial (type I) with bromobutyl coated rubber stoppers and an aluminium flip-off seal.
Maltese: Kunjett tal-ħġieġ ta' 5 ml (tip I) b'tapp tal-lastiku ta' bromobutyl u siġill tal-aluminju li jinqala bissaba'.
English: Somnolence, headache
Maltese: Ħedla, uġigħ ta' ras
English: Completed suicide, personality disorder, thinking abnormal, delirium
Maltese: Suwiċidju mitmum, disturb fil-personalità, ħsibijiet abnormali, delirju
English: The NOAEL was <200 mg/kg/day for the dams and 200 mg/kg/day for the foetuses (equal to the MRHD on a mg/m2 basis).
Maltese: In-NOAEL kien ta' <200 mg/kg/ġurnata fl-ommijiet u 200 mg/kg/ġurnata għal-feti (ugwali għal MRHD fuq bażi ta' mg/m
English: With continued long-term treatment, 47.4% of the patients were free of tonic-clonic seizures for at least 6 months and 31.5% were free of tonic-clonic seizures for at least 1 year.
Maltese: 4 % tal-pazjenti ma kellhomx aċċessjonijiet tat-tip tonic-clonic għal mill-inqas 6 xhur u 31.5 % ma kellhomx aċċessjonijiet tat-tip tonic-clonic għal mill-inqas sena.
English: This medicinal product contains 2.5 mmol (or 57 mg) sodium per maximum single dose (0.8 mmol (or 19 mg) per vial).
Maltese: Dan il-prodott mediċinali fih 2.5 mmol (jew 57 mg) sodium għal kull doża massima (0.8 mmol (jew 19 mg) f'kull kunjett).
English: With continued long-term treatment, 28.6% of the patients were free of myoclonic seizures for at least 6 months and 21.0% were free of myoclonic seizures for at least 1 year.
Maltese: B'trattament li jitkompla fit-tul, 28.6 % tal-pazjenti ma kellhomx aċċessjonjiet mijokloniċi għal mill-inqas 6 xhur u 21.0 % ma kellhomx aċċessjonjiet mijokloniċi għal mill-inqas sena.
English: The CLcr in ml/min may be estimated from serum creatinine (mg/dl) determination, for adults and adolescents weighting 50 kg or more, the following formula:
Maltese: Din ir-rata tista' tigi kkalkulata mill-livell ta' kreatinina fis-serum (mg/dl), għal adulti u adolexxenti ta' 50 kg jew aktar, billi tuża din il-formula:
English: The NOAEL (No Observed Adverse Effect Level) was 3600 mg/kg/day for pregnant female rats (x 12 the MRHD on a mg/m2 basis) and
Maltese: The NAOEL (Livell ta' Ebda Effett Avvers Osservat) kien ta' 3600 mg/kg/ġurnata għal firien feminili tqal (x 12 il-MRHD fuq bażi ta' mg/m2) u 1200 mg/kg/ġurnata għal feti.
English: • in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
Maltese: • fit-trattament ta' aċċessjonijiet primarji u ġeneralizzati tat-tip tonic-clonic f'adulti u adolexxenti minn 12-il sena b'Epilessija Ġeneralizzata Idjopatika.
English: Liver function test abnormal
Maltese: Riżultat anormali tat-test talfunzjoni epatika
English: The other ingredients are: sodium acetate trihydrate, glacial acetic acid, sodium chloride, water for injections.
Maltese: - Is-sustanzi l-oħra huma: sodium acetate trihydrate, glacial acetic acid, sodium chloride, ilma għal injezzjonijiet.
English: • delirium;
Maltese: • ferriment.
English: 1,500 mg 15 ml (three 5 ml vials)
Maltese: 1,500 mg 15 ml (tliet kunjetti ta' 5 ml)
English: Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu
Maltese: Informazzjoni dettaljata dwar din il-mediċina tinsab fuq is-sit elettroniku tal-Aġenzija Ewropea dwar il-Mediċini http://www.ema.europa.eu
English: Levetiracetam is an antiepileptic medicine (a medicine used to treat seizures (fits) in epilepsy).
Maltese: Levetiracetam huwa mediċina għal kontra l-epilessija (użata biex tittratta l-aċċessjonijiet (attakki talqamar) f‘epilessija).
English: • elevated/abnormal values in a liver function test;
Maltese: • valuri għolja/abnormali fit- testi tal-funzjonament tal-fwied;
English: Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with antiepileptic agents (including levetiracetam).
Maltese: Suwiċidju, attentat ta' suwiċidju, ħsibijiet u mġiba suwiċidali kienu rrappurtati f'pazjenti trattati b'mediċini ta' kontra l-epilessija (inkluż levetiracetam).
English: Pancytopenia, neutropenia agranulocytosis
Maltese: Panċitopenija, newtropenija agranuloċitożi
English: Metabolism and nutrition disorders
Maltese: Disturbi filmetaboliżmu u fin-nutrizzjoni
English: Concomitant administration of levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels.
Maltese: It-teħid flimkien ta' levetiracetam u methotrexate kien irrapurtat li jnaqqas clearance ta' methotrexate, li jirriżulta f'żieda / prolongament ta' konċentrazzjoni fid-demm ta' methotrexate f'livelli potenzjalment tossiċi.
English: Other ingredients include sodium acetate trihydrate, glacial acetic acid, sodium chloride, water for injections.
Maltese: Sustanzi oħra jinkludu sodium acetate trihydrate, glacial acetic acid, sodium chloride, ilma għal injezzjonijiet.
English: 1,000 mg 10 ml (two 5 ml vials) 100 ml
Maltese: 1,000 mg 10 ml (żewġ kunjetti ta' 5 ml)
English: 10 to 20 mg/kg (0.10 to 0.20 ml/kg) twice daily
Maltese: 10 sa 20 mg/kg (0.10 sa 0.20 ml/kg) darbtejn kuljum
English: Chemical and physical in-use stability of the diluted product stored in PVC bags has been demonstrated for 24 hours at 30 °C and at 2-8 °C.
Maltese: Stabilità kimika u fiżika waqt l-użu tal-prodott dilwit miżmum f'boroż tal-PVC ġiet murija għal 24 siegħa f'temperatura ta' 30
English: • amnesia (loss of memory), memory impairment (forgetfulness), abnormal coordination/ataxia
Maltese: • amneżija (telf ta' memorja), indeboliment fil-memorja (tinsa), koordinazzjoni abnormali/atassja (movimenti koordinati indeboliti), paraestesija (tnemnim), disturbi f'attenzjoni (telf ta' konċentrazzjoni);
English: • diplopia (double vision), vision blurred;
Maltese: • diplopja (viżjoni doppja), viżjoni mċajpra;
English: The dose level of 1800 mg/kg/day induced a marked maternal toxicity and a decrease in foetal weight associated with increased incidence of foetuses with cardiovascular/skeletal anomalies.
Maltese: Il-livell tad-doża ta' 1800 mg/kg/ġurnata indotta tossiċità materna notevoli u tnaqqis fil-piż tal-fetu assoċjat ma' żieda fl-inċidenza ta' feti b'anormalitajiet kardjovaskolari/skeltrali.
English: • uncontrollable muscle spasms affecting the head, torso and limbs, difficulty in controlling movements, hyperkinesia (hyperactivity);
Maltese: • spażmi muskolari mhux kontrollati li jaffettwaw ir-ras, is-sider, id-dirgħajn u r-riġlejn, diffikultà biex jiġu kontrollati l-movimenti, iperkinesja (iperattività);
English: A single dose of 1,500 mg levetiracetam diluted in 100 ml of a compatible diluent and infused intravenously over 15 minutes is bioequivalent to 1,500 mg levetiracetam oral intake, given as three 500 mg tablets.
Maltese: Doża waħda ta' 1,500 mg levetiracetam dilwita f'100 ml ta' diluwent kompatibbli u infuż ġol-vina fuq 15-il minuta hu bijoekwivalenti għal teħid orali ta' 1,500 mg levetiracetam, mogħti bħala tliet pilloli ta' 500 mg.
English: Vial of 5 ml
Maltese: Kunjett ta' 5 ml
English: Dilute before use
Maltese: Volum ta' diluwent
English: • flu-like symptoms and a rash on the face followed by an extended rash with a high temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes (Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS]).
Maltese: • sintomi bħal tal-influwenza u raxx fuq il-wiċċ segwiti minn raxx estiż u deni qawwi, żieda fillivelli tal-enzimi tal-fwied osservati fit-testijiet tad-demm u żieda f'tip ta' ċellula tad-demm bajda (eosinofilija) u tkabbir tal-għoqod tal-limfa (Reazzjoni tal-Mediċina b'Eoeinofilija u Sintomi Sistemiċi [DRESS, Drug Reaction with Eosinophilia and Systemic Symptoms])
English: Two embryo-foetal development (EFD) studies were performed in rats at 400, 1200 and 3600 mg/kg/day.
Maltese: Żewġ studji fuq l-iżvilupp tal-embriju u l-fetu (EFD) saru fil-far b'400, 1200 u 3600 mg/kg/ġurnata.
English: • suicide, personality disorders (behavioural problems), thinking abnormal (slow thinking, unable to concentrate);
Maltese: • suwiċidju, disturbi marbuta mal-personalità (problemi ta' mġieba), taħseb b'mod abnormali (taħseb bil-mod, mhux kapaċi tikkonċentra);
English: See the table below for the recommended preparation and administration of Levetiracetam Hospira concentrate to achieve a total daily dose of 500 mg, 1,000 mg, 2,000 mg, or 3,000 mg in two divided doses.
Maltese: Ara t-tabella t'hawn isfel għall-preparazzjoni rakkomandata u l-għoti ta' konċentrat ta' Levetiracetam Hospira sabiex tintlaħaq id-doża totali ta' kuljum ta' 500 mg, 1,000 mg, 2,000 mg jew 3,000 mg f'żewġ dożi maqsuma.
English: 35 infants aged less than 1 year with partial onset seizures have been exposed in placebo-control clinical studies of which only 13 were aged < 6 months.
Maltese: 35 trabi ta' inqas minn sena b' aċċessjonijiet partial onset kienu esposti f'studji kliniċi kkontrollati minn plaċebo li minnhom 13 biss kienu iżgħar minn 6 xhur.
English: The adverse reaction profile presented below is based on the analysis of pooled placebo-controlled clinical trials with all indications studied, with a total of 3,416 patients treated with levetiracetam.
Maltese: Il-profil ta' każijiet avversi t'hawn isfel hu bażat fuq analiżi minn provi kliniċi li saru bil-plaċebo bħala kontroll bl-indikazzjonijiet kollha studjati, b'total ta' 3,416-il-pazjent ikkurat b'levetiracetam.
English: 10 to 30 mg/kg (0.10 to 0.30 ml/kg) twice daily
Maltese: 10 sa 30 mg/kg (0.10 sa 0.30 ml/kg) darbtejn kuljum
English: More than half of the subjects remained seizure free for 12 months (56.6% and 58.5% of subjects on levetiracetam and on carbamazepine CR respectively).
Maltese: Iżjed min-nofs il-pazjenti baqgħu mingħajr aċċessjonijet għal 12-il xahar ( 56.6 % u 58.5 % tal-pazjenti fuq levetiracetam u fuq carbamazepine CR rispettivament).
English: Other medicines and Levetiracetam Hospira
Maltese: Mediċini oħra u Levetiracetam Hopira
English: Starting dose: 10 mg/kg twice daily
Maltese: Doża tal-bidu: 10 mg/kg darbtejn kuljum
English: No data are available.
Maltese: Dejta mhix disponibbli.
English: • symptoms such as low urine volume, tiredness, nausea, vomiting, confusion and swelling in the legs, ankles or feet, as this may be a sign of sudden decrease of kidney function
Maltese: • sintomi bħal volum baxx ta' awrina, għeja, dardir, rimettar, konfużjoni u nefħa fir-riġlejn, flgħekiesi jew fis-saqajn, għax dan jista' jkun sinjal ta' tnaqqis f'daqqa tal-funzjoni tal-kliewi
English: • sudden decrease in kidney function;
Maltese: • nuqqas f'daqqa fil-funzjoni tal-kliewi;
English: 5 to 10 mg/kg (0.05 to 0.10 ml/kg) twice daily
Maltese: 5 sa 10 mg/kg (0.05 sa 0.10 ml/kg) darbtejn kuljum
English: The pharmacokinetic profile has been characterized following oral administration.
Maltese: Il-profil farmakokinetiku ġie karaterizzat wara l-għoti orali.
English: Rhabdomyolysis and blood creatine phosphokinase increased*
Maltese: Rabdomijolożi u żieda fi creatine phosphokinase fid-demm *
English: lethargy (lack of energy and enthusiasm), tremor (involuntary trembling);
Maltese: għeja kbira (nuqqas ta' enerġija u entużjażmu), rogħda (tiċċaqlaq b'mod involontarju);
English: 1,500 twice daily Children 25 kg or less should preferably start the treatment with levetiracetam 100 mg/ml oral solution.
Maltese: 500 mg darbtejn kuljum 1500 mg darbtejn kuljum Tfal ta' 25 kg jew inqas għandhom preferabilment jibdew it-trattament b'soluzzjoni orali ta' levetiracetam 100mg/ml
English: Following dialysis, a 250 to 500 mg supplemental dose is recommended.
Maltese: (2) Wara d-dijaliżi, hija rrikkmandata doża supplimentari ta' bejn 250 u 500 mg.
English: • skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme), a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome), and a more severe form causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis);
Maltese: • raxx tal-ġilda, li jistgħu jifformaw infafet u jidhru bħal bersallji żgħir (dbabar suwed fiċ-ċentru mdawwrin b'żona aktar ċara, b'ċirku skur madwar it-tarf) (eritema multiforme), raxx mifrux b'infafet u ġilda li titqaxxar, partikularment madwar il-ħalq, l-imnieħer, l-għajnejn u l-organi ġenitali (sindromu ta' Stevens-Johnson), u forma aktar severa li tikkaġuna l-ġilda titqaxxarf'aktar minn 30% tal-wiċċ tal-ġisem (nekrolisi epidermali tossika);
English: See the table below for the recommended preparation and administration of Levetiracetam Hospira concentrate for solution for infusion to achieve a total daily dose of 500 mg, 1,000 mg, 2,000 mg, or 3,000 mg in two divided doses.
Maltese: Ara t-tabella t'hawn isfel għall-preparazzjoni rakkomandata u l-għoti tal-konċentrat ta' Levetiracetam Hospira għal soluzzjoni għall-infużjoni sabiex tintlaħaq id-doża totali ta' kuljum ta' 500 mg, 1,000 mg, 2,000 mg, jew 3,000 mg f'żewġ dożi kondiviżi.
English: • Lactated Ringer's solution for injection
Maltese: • Soluzzjoni għall-injezzjoni ta' Lactated Ringer
English: Drug reaction with eosinophilia and systemic symptoms (DRESS).
Maltese: Reazzjoni għallmediċina b'esinofilja u sintomi sistemiċi (DRESS) Ipersensittivita` (inkluż anġjoedima u anafillassi)
English: • abdominal pain, diarrhoea, dyspepsia (indigestion), vomiting, nausea;
Maltese: • uġigħ ta' żaqq, dijarea, dispepsja (indiġestjoni), remettar, tqalligħ;
English: A retrospective assessment of pharmacokinetic interactions in children and adolescents with epilepsy (4 to 17 years) confirmed that adjunctive therapy with orally administered levetiracetam did not influence the steady-state serum concentrations of concomitantly administered carbamazepine and valproate.
Maltese: Studju retrospettiv ta' interazzjoni farmakokinetika fi tfal u adolexxenti b'epilessija (4 sa 17-il sena) ikkonferma li terapija miżjuda b'levetitacetam li jittieħed mill-ħalq ma kellux effett fuq konċentrazzjonijiet tas-serum fi stat fiss ta' carbamazepine u valproate li jingħataw fl-istess ħin.
English: Twice daily 2,000 mg/day
Maltese: 15-il minuta Darbtejn kuljum2,000 mg/ ġurnata
English: Creatinine clearance (ml/min/1.73 m
Maltese: Tneħħija ta' kreatinina (ml/min/1.73 m
English: 500 to 1,500 mg twice daily
Maltese: 500 sa 1,500 mg darbtejn kuljum
English: If levetiracetam has to be discontinued it is recommended to withdraw it gradually (e.g. in adults and adolescents weighing more than 50 kg: 500 mg decreases twice daily every two to four weeks; in children and adolescents weighting less than 50 kg: dose decrease should not exceed 10 mg/kg twice daily every two weeks).
Maltese: Jekk levetiracetam għandu jitwaqqaf hu rrikkmandat li jitwaqqaf gradwalment (ez. f'adulti u adoloxxenti li jiżnu iżjed minn 50 kg: tnaqqis ta' 500 mg darbtejn kuljum kull ġimagħtejn sa erba ġimgħat; f'tfal u adoloxxenti li jiżni inqas minn 50 kg: it-tnaqqis fid-doża m'għandiex taċċedi 10 mg/kg darbtejn kuljum kull ġimagħtejn).
English: • a more severe form of rash causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis)
Maltese: • forma aktar severa ta' raxx li jikkawża tqaxxir tal-ġilda fuq aktar minn 30% tal-wiċċ tal-ġisem (nekrolisi epidermali tossika)
English: In several cases of alopecia, recovery was observed when levetiracetam was discontinued.
Maltese: F'diversi każi ta' alopeċja, kien osservat irkupru meta twaqqaf levetiracetam.
English: Levetiracetam and related analogues show a rank order of affinity for binding to the synaptic vesicle protein 2A which correlates with the potency of their anti-seizure protection in the mouse audiogenic model of epilepsy.
Maltese: Levetiracetam u sustanzi relatati oħra juru affinità li jeħlu mal-proteina tal-bużżieqa tas-sinapsi 2A b'rata li tikkorralata mal-qawwa tal-protezzjoni li jagħtu kontra l-aċċessjonijiet fil-mudell talepilessija awdjoġeniku fil-ġurdien.